GleamWall
中文EN

NAUT Nautilus Biotechnology, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1808805 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.0%
ROA-33.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity0.00x
Current ratio9.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$234,000$190,000——$0$0——
Cost of revenue$24,000$15,000——$0$0——
Gross profit$210,000$175,000——$0$0——
R&D expense$10.18M$9.61M$9.71M$9.57M$9.61M$10.39M$11.54M$12.82M
SG&A expense$6.77M$6.33M$6.42M$5.85M$5.87M$6.70M$7.31M$7.16M
Income tax$0$0$0$0$0$0$0$0
Net income-$15.64M-$14.47M-$14.70M-$13.78M-$13.57M-$15.03M-$16.61M-$17.59M
EPS (basic)-0.12-0.11-0.12—-0.11-0.12-0.13—
EPS (diluted)-0.12-0.11-0.12—-0.11-0.12-0.13—
Weighted avg. shares (diluted)127.24M127.14M126.63M—126.31M126.20M126.14M—
Balance sheet
Cash & equivalents$10.47M$13.17M$14.63M$12.39M$24.88M$35.46M$34.24M$28.65M
Short-term investments$76.11M$70.86M$81.24M$91.02M$107.55M$113.42M$105.57M$102.25M
Inventory$900,000$600,000$300,000—————
Current assets$90.24M$87.63M$98.83M$105.96M$134.32M$150.72M$141.60M$132.83M
PP&E, net$5.27M$4.00M$3.63M$3.46M$3.62M$3.73M$3.79M$4.08M
Total assets$148.92M$163.58M$177.78M$191.11M$200.91M$213.19M$227.69M$242.74M
Current liabilities$9.76M$8.64M$8.34M$7.95M$8.98M$8.14M$8.16M$7.63M
Total liabilities$32.37M$32.46M$33.36M$34.14M$31.78M$32.09M$33.26M$34.01M
Shareholders' equity$116.56M$131.11M$144.41M$156.97M$169.14M$181.09M$194.44M$208.73M
Shares outstanding127.33M127.22M127.07M126.47M126.31M126.31M126.15M126.11M
Cash flow statement
Operating cash flow-$13.28M-$13.73M-$13.10M-$12.38M-$11.03M-$13.35M-$13.94M-$14.31M
Capital expenditure$1.45M$454,000$510,000$244,000$418,000$396,000$219,000$254,000
Free cash flow-$14.73M-$14.18M-$13.61M-$12.62M-$11.45M-$13.75M-$14.16M-$14.56M
Investing cash flow$10.44M$12.02M$14.23M$787,000$452,000$14.47M$19.51M$37.11M
Financing cash flow$26,000$244,000$1.10M$101,000$0$95,000$18,000$440,000
Depreciation & amortization$200,000$300,000$334,000$352,000$400,000$400,000$465,000$432,000
Stock-based compensation$1.29M$1.16M$1.36M$1.47M$1.50M$1.71M$2.17M$3.12M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.